SomaGenics: $2.275M in NIH grants, four patents, and more

Share This:

email

Twitter

Linkedin

Facebook

Sara Isenberg
Santa Cruz Tech Beat, Publisher

Translating RNA discoveries into innovative products

Santa Cruz Tech Beat published Six Companies to Watch in the Emerging Santa Cruz Biotech Hub almost a year ago (February 27, 2014).

SomaGenics was one of those companies to watch.

Originally incorporated in 1997 as a technology spin-out from SRI, the company is now located on Delaware Avenue, in Santa Cruz.

Good news to start the new year

Last month, SomaGenics announced several items of good news.

1. SomaGenics was recently awarded $2,275,000 in Small Business Innovation Research (SBIR) grants from the NIH to further develop and expand its RNA-based technologies in the areas of wound healing, hepatitis delta virus (HDV) therapeutics, microRNA (miRNA) expression profiling, and next-generation sequencing. Read more…
2. SomaGenics recently had four patents covering various aspects of its small RNA platform technologies issued or allowed by the US and European Patent Offices. Read more…
3. SomaGenics and collaborators recently published exciting results on the efficacy of RNA interference (RNAi) therapeutics against the hepatitis C virus (HCV) based on the company’s sshRNA™ platform. Read more…

For more information:

• SomaGenics website
• Three Somagenics Publications Demonstrate Successful Inhibition of the Hepatitis C Virus by Therapeutic sshRNA™ and Confirm Mechanism of Action
• SomaGenics Receives $2,275,000 in NIH Funding to Develop its RNAi Therapeutics and microRNA Technologies
• SomaGenics Awarded Four Patents Spanning Its miRNA and RNAi Programs

###

Tagged Somagenics